Breaking News Instant updates and real-time market news.

Halozyme Therapeutics announced that its investigational drug, PEGPH20, and a companion diagnostic assay for assessment of hyaluronan under development by Ventana Medical Systems will be included in a pancreatic cancer clinical trial initiative called Precision Promise. The Precision Promise initiative aims to change the current treatment approach to pancreatic cancer, offering options to patients based on the molecular profile of their tumor. Precision Promise plans to enroll patients at 12 initial consortium sites in Spring 2017.

HALOHalozyme

$12.24

0.16 (1.32%)

01/20/16

UBSW

01/20/16NO CHANGETarget $22UBSWBuy

Halozyme price target lowered to $22 from $28 at UBS

UBS lowered its price target on Halozyme to $22 from $28 due to the recent market weakness in the biotech sector. The firm said the company's recent data on its drug was not well received, but still suggests a potential new standard of care in pancreatic cancer. UBS maintained its Buy rating on Halozyme shares.

02/01/16

ADAM

02/01/16INITIATIONTarget $10ADAMBuy

Halozyme initiated with a Buy at Canaccord

Target $10.

02/01/16

02/01/16INITIATION

On The Fly: Analyst Initiation Summary

Today's noteworthy initiations include: Acadia (ACHC) initiated with an Overweight at KeyBanc... Altisource Residential (RESI) initiated with a Neutral at Nomura... Colony Starwood Homes (SFR) initiated with a Buy at Nomura... EyeGate (EYEG) initiated with a Buy at Rodman & Renshaw... Fortinet (FTNT) initiated with an Outperform at Northland... Halozyme (HALO) initiated with a Buy at Canaccord... Lendingtree (TREE) initiated with an Outperform at Northland... Lindblad Expeditions (LIND) initiated with an Outperform at Credit Suisse... Summit Therapeutics (SMMT) initiated with a Buy at Canaccord... VolitionRx (VNRX) initiated with a Buy at Rodman & Renshaw.

09/16/16

PIPR

09/16/16NO CHANGETarget $18PIPROverweight

Halozyme price target raised to $18 from $15 at Piper Jaffray

Piper Jaffray analyst Charles Duncan raised his price target for Halozyme Therapeutics to $18 after hosting investor meetings with management. The analyst now has increased conviction in the long-term value of the company's ENHANZE products. He reiterates an Overweight rating on the shares.

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chesapeake Utilities (CPK) initiated with a Neutral at Ladenburg. 2. CONSOL (CNX) initiated with a Neutral at Goldman. 3. Johnson Controls (JCI) assumed with an Equal Weight at Barclays. 4. American Midstream Partners (AMID) initiated with a Buy at Janney Capital. 5. Brookfield Infrastructure (BIP) coverage resumed with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Abercrombie & Fitch (ANF) downgraded to Sell from Hold at Argus with analysts John Eade and Katelyn Bayone citing the company's third quarter miss and what they see as its "challenging sales outlook for the remainder of the year." 2. Duluth Holdings (DLTH) downgraded to Hold from Buy at Stifel and to Market Perform from Outperform at William Blair. 3. DAVIDsTEA (DTEA) downgraded to Market Perform from Outperform at BMO Capital and to Market Perform from Outperform at William Blair. 4. Hilton (HLT) downgraded to Outperform from Buy at CLSA with analyst Jon Oh citing valuation. 5. Horizon Pharma (HZNP) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez saying the recent weakness in shares provides an "excellent entry point" ahead of several critical pipeline events that have the potential "to transform this giant into an exciting growth story." 2. Autodesk (ADSK) upgraded to Buy from Hold at Canaccord with analyst Richard Davis citing expectations for improved free cash flow, as he sees a path to $6 in FCF by 2020 and $11 per share in 2022. 3. Eaton (ENT) upgraded to Overweight from Neutral at JPMorgan with analyst Ann Duignan saying optionality of the company's balance sheet should offset broad weakness across its end markets. 4. Fluor (FLR) upgraded to Buy from Neutral at Citi with analyst Andrew Kaplowitz saying the company is positioned to outperform given amid oil and gas capex stabilization, a lift off the bottom in mining off the bottom and "muted" 2017 expectations. 5. Sysco (SYY) upgraded to Neutral from Sell at Goldman. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.